There are many contributing factors to the predicted boom in the ophthalmic drugs market. We live in a world where people are living to much greater ages, as well as a huge prevalence of lifestyle-associated diseases, such as diabetes and high blood pressure. All of these can lead to the onset of eye-related disorders. As a result of this there is an ever increasing worldwide prevalence of eye-related disorders and across this population there are a vast array of different disorders that people suffer from. This means the demand for treatments is inevitably going to increase.
In 2012 reports showed that the worldwide ophthalmic drug market was worth around $16 billion. This figure is expected to increase to well above $21 billion by 2018. Conditions such as Diabetic Retinopathy and Age-Related Macular Degeneration (AMD) are amongst the most commonly suffered eye-disorders, but Glaucoma treatment actually holds the highest market share in the ophthalmic drug market.
As a result of this there are also increasing numbers of government initiatives centred on healthcare infrastructure which place great emphasis on such matters. At present countries such as China, India areas of the Eastern Mediterranean have rapidly growing ophthalmic drug markets and the World Health Organisation (WHO) has reported that the number of people above the age of 50 who go blind in these countries will continue to rise, further fuelling the demand for drugs. In contrast to this, combating blindness and degenerative eye diseases is already a driving factor in the market in places such as North America and Western Europe.
(Image by http://www.freedigitalphotos.net/)